Galapagos NV
GLPG
Company Profile
Business description
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients’ lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
Contact
Generaal De Wittelaan L11 A3
Mechelen2800
BELT: +32 15342900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
646
Stocks News & Analysis
stocks
Better times ahead for these cheap ASX shares?
Our analysts think the outlook looks fairly good for these two undervalued and unloved ASX dividend payers.
video
ASX dividend stocks for 2025
With dividend yields at 25-year lows, it's time to rethink ASX stocks for income according to James Gruber.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,691.90 | 64.80 | -0.74% |
| CAC 40 | 8,206.56 | 17.43 | 0.21% |
| DAX 40 | 22,844.50 | 46.41 | 0.20% |
| Dow JONES (US) | 44,556.34 | 10.26 | 0.02% |
| FTSE 100 | 8,766.73 | 1.28 | -0.01% |
| HKSE | 22,911.62 | 65.19 | -0.28% |
| NASDAQ | 20,041.26 | 14.49 | 0.07% |
| Nikkei 225 | 39,132.67 | 137.73 | -0.35% |
| NZX 50 Index | 13,033.36 | 17.76 | -0.14% |
| S&P 500 | 6,129.58 | 14.95 | 0.24% |
| S&P/ASX 200 | 8,410.70 | 70.30 | -0.83% |
| SSE Composite Index | 3,342.48 | 17.99 | 0.54% |